322 11th Avenue SW
Suite 804
Calgary, AB T2R 0C5
Canada
403 670 7377
https://www.oncolyticsbiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Matthew C. Coffey M.B.A., Ph.D. | President, CEO & Director | 798.1k | N/D | N/D |
Mr. Kirk J. Look C.A., CA | Chief Financial Officer | 557.75k | N/D | N/D |
Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 614.38k | N/D | N/D |
Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 423.7k | N/D | N/D |
Ms. Amy Goodowitz Levin | Vice President of Clinical Operations | 408.2k | N/D | N/D |
Jon Patton | Director of Investor Relations & Communication | N/D | N/D | N/D |
Mr. John Mark Lievonen BBA, C.M., FCA, LLD, MBA | Consultant | 19.12k | N/D | N/D |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
La calificación ISS Governance QuickScore de Oncolytics Biotech Inc. a partir del 1 de marzo de 2024 es 4. Las puntuaciones principales son Auditoría: 5; Junta: 1; Derechos del accionista: 2; Compensación: 9.